Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.35 Billion EUR | -7.96% |
| 2022 | 4.73 Billion EUR | -8.83% |
| 2021 | 5.19 Billion EUR | -9.17% |
| 2020 | 5.71 Billion EUR | -5.78% |
| 2019 | 6.06 Billion EUR | 321.58% |
| 2018 | 1.43 Billion EUR | 11.91% |
| 2017 | 1.28 Billion EUR | 18.73% |
| 2016 | 1.08 Billion EUR | 144.81% |
| 2015 | 442.51 Million EUR | 63.61% |
| 2014 | 270.46 Million EUR | -5.88% |
| 2013 | 287.37 Million EUR | 22.12% |
| 2012 | 235.32 Million EUR | 46.12% |
| 2011 | 161.05 Million EUR | -16.97% |
| 2010 | 193.96 Million EUR | 34.97% |
| 2009 | 143.7 Million EUR | 20.94% |
| 2008 | 118.82 Million EUR | -20.1% |
| 2007 | 148.72 Million EUR | -11.29% |
| 2006 | 167.64 Million EUR | 105.54% |
| 2005 | 81.56 Million EUR | 422.4% |
| 2004 | 15.61 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.36 Billion EUR | 0.09% |
| 2024 Q3 | 4.17 Billion EUR | -2.75% |
| 2024 Q2 | 4.29 Billion EUR | -1.63% |
| 2023 Q3 | 4.45 Billion EUR | -1.57% |
| 2023 Q2 | 4.52 Billion EUR | -2.37% |
| 2023 Q1 | 4.63 Billion EUR | -2.16% |
| 2023 FY | 4.35 Billion EUR | -7.96% |
| 2023 Q4 | 4.35 Billion EUR | -2.11% |
| 2022 FY | 4.73 Billion EUR | -8.83% |
| 2022 Q1 | 5.1 Billion EUR | -1.79% |
| 2022 Q2 | 5.04 Billion EUR | -1.18% |
| 2022 Q4 | 4.73 Billion EUR | -4.78% |
| 2022 Q3 | 4.97 Billion EUR | -1.35% |
| 2021 Q1 | 5.61 Billion EUR | -1.8% |
| 2021 Q2 | 5.43 Billion EUR | -3.28% |
| 2021 Q4 | 5.19 Billion EUR | -2.6% |
| 2021 Q3 | 5.33 Billion EUR | -1.82% |
| 2021 FY | 5.19 Billion EUR | -9.17% |
| 2020 Q2 | 5.85 Billion EUR | -2.35% |
| 2020 Q3 | 5.72 Billion EUR | -2.23% |
| 2020 Q4 | 5.71 Billion EUR | -0.06% |
| 2020 FY | 5.71 Billion EUR | -5.78% |
| 2020 Q1 | 5.99 Billion EUR | -1.26% |
| 2019 Q4 | 6.06 Billion EUR | 3.71% |
| 2019 FY | 6.06 Billion EUR | 321.58% |
| 2019 Q1 | 1.4 Billion EUR | -2.73% |
| 2019 Q3 | 5.85 Billion EUR | 330.96% |
| 2019 Q2 | 1.35 Billion EUR | -3.02% |
| 2018 Q1 | 1.22 Billion EUR | -4.39% |
| 2018 Q3 | 1.48 Billion EUR | 23.35% |
| 2018 FY | 1.43 Billion EUR | 11.91% |
| 2018 Q4 | 1.43 Billion EUR | -3.1% |
| 2018 Q2 | 1.2 Billion EUR | -2.07% |
| 2017 FY | 1.28 Billion EUR | 18.73% |
| 2017 Q4 | 1.28 Billion EUR | -3.39% |
| 2017 Q3 | 1.33 Billion EUR | -2.7% |
| 2017 Q2 | 1.36 Billion EUR | 27.55% |
| 2017 Q1 | 1.07 Billion EUR | -0.97% |
| 2016 Q4 | 1.08 Billion EUR | 3.86% |
| 2016 FY | 1.08 Billion EUR | 144.81% |
| 2016 Q1 | 1.07 Billion EUR | 143.9% |
| 2016 Q2 | 1.06 Billion EUR | -1.18% |
| 2016 Q3 | 1.04 Billion EUR | -2.2% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q2 | 488.26 Million EUR | 0.0% |
| 2015 FY | 442.51 Million EUR | 63.61% |
| 2015 Q4 | 442.51 Million EUR | -4.02% |
| 2015 Q3 | 461.04 Million EUR | -5.57% |
| 2014 Q4 | 270.46 Million EUR | 0.0% |
| 2014 Q2 | 304.98 Million EUR | 0.0% |
| 2014 Q1 | 304.98 Million EUR | 6.13% |
| 2014 FY | 270.46 Million EUR | -5.88% |
| 2013 FY | 287.37 Million EUR | 22.12% |
| 2013 Q3 | 287.37 Million EUR | 4.04% |
| 2013 Q2 | 276.22 Million EUR | 0.0% |
| 2013 Q4 | 287.37 Million EUR | 0.0% |
| 2013 Q1 | 276.22 Million EUR | 17.38% |
| 2012 Q3 | 235.32 Million EUR | -3.29% |
| 2012 Q4 | 235.32 Million EUR | 0.0% |
| 2012 FY | 235.32 Million EUR | 46.12% |
| 2012 Q2 | 243.33 Million EUR | 0.0% |
| 2011 Q2 | 152.98 Million EUR | 0.0% |
| 2011 FY | 161.05 Million EUR | -16.97% |
| 2011 Q4 | 161.05 Million EUR | 0.0% |
| 2010 Q2 | 139.73 Million EUR | 0.0% |
| 2010 FY | 193.96 Million EUR | 34.97% |
| 2010 Q4 | 193.96 Million EUR | 0.0% |
| 2009 Q2 | 106.21 Million EUR | 0.0% |
| 2009 FY | 143.7 Million EUR | 20.94% |
| 2009 Q4 | 143.7 Million EUR | 0.0% |
| 2008 FY | 118.82 Million EUR | -20.1% |
| 2008 Q4 | 118.82 Million EUR | 0.0% |
| 2007 FY | 148.72 Million EUR | -11.29% |
| 2006 FY | 167.64 Million EUR | 105.54% |
| 2005 FY | 81.56 Million EUR | 422.4% |
| 2004 FY | 15.61 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -29521.999% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -1232.284% |
| Adocia SA | 24.95 Million EUR | -17360.314% |
| Aelis Farma SA | 26.28 Million EUR | -16480.024% |
| Biophytis S.A. | 11.93 Million EUR | -36406.334% |
| Advicenne S.A. | 12.4 Million EUR | -35020.464% |
| genOway Société anonyme | 31.84 Million EUR | -13584.27% |
| IntegraGen SA | 8 Million EUR | -54365.06% |
| Medesis Pharma S.A. | 1.92 Million EUR | -226101.362% |
| Neovacs S.A. | 47.53 Million EUR | -9066.982% |
| NFL Biosciences SA | 3.97 Million EUR | -109640.726% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -29118.923% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -116197.366% |
| Sensorion SA | 46.49 Million EUR | -9271.938% |
| Theranexus Société Anonyme | 7.23 Million EUR | -60103.845% |
| TME Pharma N.V. | 2.49 Million EUR | -174825.572% |
| Valbiotis SA | 33.24 Million EUR | -13005.739% |
| TheraVet SA | 7.53 Million EUR | -57734.963% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -12252.997% |
| argenx SE | 4.11 Billion EUR | -5.965% |
| BioSenic S.A. | 9.55 Million EUR | -45484.224% |
| Celyad Oncology SA | 16.28 Million EUR | -26662.044% |
| DBV Technologies S.A. | 165.65 Million USD | -2530.473% |
| Genfit S.A. | 173.87 Million EUR | -2406.094% |
| GeNeuro SA | 6.31 Million EUR | -68923.682% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -9038.642% |
| Innate Pharma S.A. | 184.19 Million EUR | -2265.669% |
| Inventiva S.A. | 69.13 Million EUR | -6202.371% |
| MaaT Pharma SA | 42.93 Million EUR | -10049.766% |
| MedinCell S.A. | 36.94 Million EUR | -11693.32% |
| Nanobiotix S.A. | 93.89 Million EUR | -4540.613% |
| Onward Medical N.V. | 43.62 Million EUR | -9887.385% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -3976.137% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -5220.386% |
| Oxurion NV | 6.55 Million EUR | -66425.13% |
| Pharming Group N.V. | 426.33 Million EUR | -922.048% |
| Poxel S.A. | 4.82 Million EUR | -90246.175% |
| GenSight Biologics S.A. | 9.08 Million EUR | -47851.975% |
| Transgene SA | 45.21 Million EUR | -9536.632% |
| Financière de Tubize SA | 1.92 Billion EUR | -126.919% |
| UCB SA | 15.53 Billion EUR | 71.958% |
| Valneva SE | 469.39 Million EUR | -828.308% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -14034.082% |